<DOC>
	<DOCNO>NCT00716417</DOCNO>
	<brief_summary>Study determine maximum tolerate dose BIBW 2992 combine backbone chemotherapy consist cisplatin plus paclitaxel cisplatin plus 5 FU . The overall safety , pharmacokinetics anti-tumour efficacy also assess .</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose BIBW 2992 ( Afatinib ) When Combined With Cisplatin/Paclitaxel Cisplatin/5-FU Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm diagnosis non resectable / metastatic cancer , preferably squamous cell carcinoma head neck , oesophagus , lung cervix 2 . Indication standard treatment either cisplatin plus paclitaxel cisplatin plus 5 FU judge investigator 3 . Age 18 year old . 4 . Life expectancy least three ( 3 ) month . 5 . Written inform consent consistent ICHGCP guideline . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . 7 . Patients must recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy . 8 . Patients recover previous surgery . Exclusion criterion : 1 . Active infectious disease . 2 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhoea . 3 . Serious illness concomitant nononcological disease consider investigator incompatible protocol . 4 . Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least four ( 4 ) week , history cerebral oedema bleed past four ( 4 ) week requirement steroid antiepileptic therapy . 5 . Cardiac leave ventricular function rest ejection fraction le 50 % 6 . Absolute neutrophil count ( ANC ) less 1500 / mm3 . 7 . Platelets count less 100 000/mm3 . 8 . Bilirubin 1.5 x upper limit institutional norm . 9 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) 3 x upper limit institutional norm . 10 . Serum creatinine 1.5 x upper limit institutional norm . 11 . Women men sexually active unwilling use medically acceptable method contraception . 12 . Pregnancy breastfeed . 13 . Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy participation another clinical study anticancer therapy within past 4 week start therapy concomitantly study . 14 . Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( 2 week trastuzumab ) . 15 . Patients unable comply protocol . 16 . Active alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>